Biogen Idec Inc (BIIB) 311.94 $BIIB Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Jul 29, 2015 at 12:21 PM

Biogen Idec Inc (BIIB) 311.94 $BIIB

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - 33 mins ago
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 311.94 (-7.99), VRTX: 128.32 (+0.02), ALXN: 202.92 (-0.63), AMGN: 171.81 (-0.93), ABBV: 71.29 (+0.06), REGN: 541.87 (-10.58), XOMA: 0.83 (-0.05)

Make Sure You Don't Get Caught in a Breakdown
at The Street - 2 hrs 10 mins ago
Nothing much sticks out to the upside right now.
BIIB: 311.94 (-7.99), ESPR: 65.31 (-3.70), VDSI: 21.17 (-5.38), FB: 95.51 (+0.22), BEAT: 11.83 (-0.16), DATA: 103.86 (-23.21)

Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 11 mins ago
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 311.94 (-7.99), F: 15.09 (+0.26), RIG: 14.33 (+0.21), GILD: 116.89 (+3.82), PFE: 35.75 (+0.40), COP: 52.85 (+0.61), XOM: 82.66 (+0.18), AMGN: 171.81 (-0.93), DD: 56.17 (+0.27), CVX: 92.76 (+0.36), SLB: 83.51 (+1.01), UPS: 101.78 (+1.84), CELG: 133.94 (-1.48)

5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 73.12 (+0.22), ZINC: 8.09 (+0.19), BIIB: 311.94 (-7.99), MJN: 89.79 (-0.30), DPZ: 112.16 (+0.39)

Biogen Stock Remains Deeply Oversold
at The Street - Wed Jul 29, 5:00AM CDT
Three ways to profit after last Friday's crazy freefall.
BIIB: 311.94 (-7.99)

Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
at The Street - Tue Jul 28, 3:15PM CDT
Gilead Sciences will not be blamed for a cooling of the biotech bull market, if any such thing exists.
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82)

Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 337.84 (-1.66), BIIB: 311.94 (-7.99), SHPG: 267.16 (+3.91), MYL: 57.06 (+0.71), AMGN: 171.81 (-0.93), ABBV: 71.29 (+0.06), TEVA: 71.16 (-0.25)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.
PR Newswire - Tue Jul 28, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company"

(NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
BIIB: 311.94 (-7.99)

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 157.02 (-3.30), BIIB: 311.94 (-7.99), LGND: 103.18 (-2.66), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32)

Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 311.94 (-7.99), TEVA: 71.16 (-0.25)

3 Big Biotech Buybacks That Investors Should Love
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jul 28, 6:03AM CDT
Source: Images Of Money/Flickr Creative Commons. Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found...
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), CELG: 133.94 (-1.48)

Biogen & the Parkinson's Institute and Clinical Center reports strategic alliance to form novel tools and programmes to accelerate research and the development of new treatments in Parkinson's disease
M2 - Tue Jul 28, 5:33AM CDT
Biotechnology company Biogen (NasdaqGS:BIIB) revealed on Monday the establishment of a strategic alliance with the Parkinson's Institute and Clinical Center, to enhance the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programmes that could accelerate research and the development of new PD treatments.
BIIB: 311.94 (-7.99)

'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
at The Street - Tue Jul 28, 5:00AM CDT
Cramer thinks Cerus is a nice speculative stock, says to wait on ConocoPhillips and to buy 3M at $142.
CERS: 5.46 (+0.06), MMM: 151.31 (+0.20), BIIB: 311.94 (-7.99), ISIS: 53.20 (-1.20), MDSO: 54.08 (-0.16), COP: 52.85 (+0.61), SNDK: 60.64 (-0.44)

Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs
at The Street - Mon Jul 27, 7:16PM CDT
Cramer says this is the thinnest market we've seen in ages, and that's not good.
CERS: 5.46 (+0.06), MMM: 151.31 (+0.20), AMZN: 527.32 (+1.29), BIIB: 311.94 (-7.99), MDLZ: 42.98 (+0.18), EA: 71.42 (-0.38), SNA: 162.96 (+1.83), NKE: 114.31 (+0.84), MDSO: 54.08 (-0.16), FB: 95.51 (+0.22), FCX: 12.33 (unch), COP: 52.85 (+0.61), DIS: 119.42 (+0.96), NFLX: 107.34 (+0.44), ISIS: 53.20 (-1.20), QLIK: 39.87 (-0.80), KHC: 77.11 (-1.21), GOOGL: 656.11 (-3.55), ULTA: 166.12 (+0.11), CMCSA: 62.42 (+0.01), GIS: 57.47 (-0.08), SNDK: 60.64 (-0.44)

Which Big-Cap Stocks Are Defying Market Pressure?
at Investor's Business Daily - Mon Jul 27, 5:46PM CDT
When an uptrend comes under pressure, some stocks show action worthy of a drumroll, while others inspire eye rolls. The recent trouble for the uptrend started after the July 20 close. The S&P 500 suffered four distribution days in a row through...
BIIB: 311.94 (-7.99), MNST: 149.64 (-0.35), VRX: 255.33 (-2.62), GILD: 116.89 (+3.82), CMG: 737.61 (+6.83)

5 Things Biogen's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 27, 5:00PM CDT
Biogen held a conference call in conjunction with its second-quarter earnings last week. Here are five things that management said that investors should be paying attention to. "We had expected to see a reacceleration of Tecfidera this quarter,...
BIIB: 311.94 (-7.99)

Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 337.84 (-1.66), BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), TEVA: 71.16 (-0.25), TWTR: 31.80 (-4.74)

Is the U.S. Bull Market Starting to Lose Its Luster?
at The Street - Mon Jul 27, 2:04PM CDT
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
BIIB: 311.94 (-7.99), PRGO: 193.10 (+1.03), XOM: 82.66 (+0.18), MYL: 57.06 (+0.71), BMY: 64.50 (-0.16), AGN: 337.84 (-1.66), ISRG: 540.37 (+0.11), SBUX: 57.33 (+0.19), HCA: 93.77 (+1.48), IBM: 160.93 (+0.88), GM: 31.74 (+0.42), TEVA: 71.16 (-0.25), SPLK: 68.15 (-2.74), REGN: 541.87 (-10.58), NVS: 103.83 (+1.04)

4 Stocks Breaking Out on Big Volume
at The Street - Mon Jul 27, 1:30PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
BIIB: 311.94 (-7.99), TERP: 30.73 (-0.52), WAB: 100.64 (+1.02), ENTA: 47.40 (-0.65)

Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
at The Street - Mon Jul 27, 11:32AM CDT
Tech stocks were on the minds of viewers Monday morning when they posed their questions to TheStreet's Jim Cramer, including Intel, T-Mobile and PayPal.
BIIB: 311.94 (-7.99), GILD: 116.89 (+3.82), ALTR: 49.42 (-0.06), XON: 60.63 (+0.03), PYPL: 37.91 (+0.31), TMUS: 37.00 (+0.08), TWTR: 31.80 (-4.74), INTC: 29.05 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 342

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...